



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Moussaoui-Mrabet et al.**

Examiner: **Falk, A.**

Art Unit: **1632**

Application No.: **10/088,138**

Filed: **November 25, 2002**

Title: **NOVEL ANIMAL MODEL OF  
ALZHEIMER DISEASE WITH  
AMYLOID PLAQUES AND  
MITOCHONDRIAL DYSFUNCTIONS**

<b>Certificate of Mailing or Transmission</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	<u>Feb 7, 2006</u>
Printed Name of Person Signing Certificate	<u>D. Crupen</u>
Signature	<u>D. Crupen</u>

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Karen I. Krupen, Reg. No. 34,647  
Attorney for Applicant

sanofi-aventis Inc. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626

sanofi-aventis Docket No. ST99040 US PCT